Eli Lilly’s Manjaro gains on Novo Nordisk’s Wegovy in UK By Investing.com

A significant shift is happening in the UK’s weight loss drug market as Eli Lilly (NYSE:)’s Manjaro started outpacing Novo Nordisk (NYSE:)’s Wegovy among British customers paying for obesity treatments. Online pharmacy reports indicate a growing preference for Manjaro over its rival, signaling Eli Lilly’s advancement against the European pharmaceutical company.

Manjaro has become increasingly appealing to consumers due to its higher efficacy in clinical trials conducted prior to the drugs’ approvals. The data revealed that while Wegovy enabled patients to lose an average of 15% of their body weight, Manjaro led to nearly 23% weight loss, a notable difference in outcomes.

Despite its growing popularity, Manjaro is not yet available through the UK’s National Health Service (NHS). However, projections suggest that it may become accessible via the NHS in the next year. In contrast, Wegovy has a limited availability through the NHS, restricted to specialist obesity clinics and certain qualifying circumstances.

Eli Lilly launched Manjaro in the UK in February, marking one of the first markets outside the United States where the drug became available. Wegovy has been on the UK market since 2023, in a country where approximately two-thirds of adults are considered to be overweight or obese, indicating a significant potential customer base for these obesity treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.